科瑞产品

- 客户定制产品 - 前列腺素系列 - PI3K Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - mTOR Inhibitors - c-Met Inhibitors - DNA/RNA Inhibitors - HER2 Inhibitors - Raf Inhibitors - JAK Inhibitors - Others - SRC Inhibitors - AKT Inhibitors - CDK Inhibitors

浙江省台州市椒江开发大道东段288号万达广场2号楼

0576-88813233

0576-88670057

sales@crene.cn

合作客户/Partner

当前位置：科瑞产品

维拉卡肽 Etelcalcetide

规格	价格	库存	数量
在线咨询大包装询价加入购物车

如您需要更多数量的报价，请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您，谢谢！

产品信息

产品名称：维拉卡肽 Etelcalcetide	纯度：98% min
CAS NO：1262780-97-1	溶解度：
分子式：C₃₈H₇₃N₂₁O₁₀S₂	包装：可按客户要求包装
分子量：1048.25	贮存：-20℃

质量控制

备注说明

Etelcalcetide, also known as AMG 416 and KAI-4169, is a D-amino peptide calcimimetic undergoing clinical evaluation for the treatment of secondary hyperparathyroidism for patients with chronic kidney disease (CKD) on hemodialysis. Etelcalcetide is administered intravenously at the end of each dialysis session. It functions by binding to and activating the calcium-sensing receptor (CaSR) in the parathyroid gland as an allosteric activator, resulting in PTH reduction and suppression. Elevated PTH is often observe in patients with CKD.

参考文献

1: Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Shinoda A, Akizawa T. The influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism. Nephrology (Carlton). 2019 Nov 25. doi: 10.1111/nep.13682. [Epub ahead of print] PubMed PMID: 31765028.

2: Dörr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Loewe C, Marculescu R, Erben R, Oberbauer R. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD). Trials. 2019 Oct 24;20(1):601. doi: 10.1186/s13063-019-3707-7. PubMed PMID: 31651370; PubMed Central PMCID: PMC6813957.